Fellow Eye Involvement in Low Compliance Patient with Non-Arteritic Ischemic Optic Neuropathy: A Case Report
Article Sidebar
-
NAION, ischemic optic neuropathy, fellow eye NAION
Abstract
Introduction: The incidence of fellow eye involvement in non-arteritic anterior ischemic optic neuropathy (NAION) is 15% at 5 years after initial onset, although risk factors have not been identified. The aim of this article is to determine the risk factor that could influence the fellow eye involvement with NAION.
Case Report: A 72 year-old male presented with gradual painless vision loss in the left eye (LE) for 3 months. He did not have smoking habit. BCVA on the LE was 3/60 and RAPD was present. Funduscopic examination showed optic disc atrophy on LE. Humphrey test revealed altitudinal pattern on LE with visual field index (VFI) 63%. OCTA showed significant decreased capillary perfusion on LE retinal nerve fiber layer thinning and poor capillary perfusion on LE while the right eye (RE) was normal. Laboratory examination indicated diabetes mellitus, dyslipidaemia, and hypercoagulable state. He was prescribed antidiabetic medication, antithrombotic therapy, and statin. After a month, patient showed improvement in both ocular and laboratory examinations. He was advised to continue treatment until the next visit, but he didn’t comply. Two months later, patient was presented with painless vision loss, edematous optic disc, and altitudinal visual field defect in the RE. Laboratory examination also revealed unsatisfactory results.
Discussion: Prior studies discovered that hypercoagulable states potentially contribute to NAION, presumably due to altered blood viscosity, which further leads to vascular occlusion. Our case showed hypercoagulable state patient with increased d-Dimer and fibrinogen level. Antithrombotic therapy was found beneficial to improve patient’s symptoms. However, he did not comply to therapy, thus vision loss of the fellow eye occurred.
Conclusion: Non-compliant behaviour of patient could be the risk factor for fellow eye involvement.
Full text article
References
Hayreh SS. Ischemic optic neuropathies - Where are we now? Graefe’s Arch Clin Exp Ophthalmol. 2013;251(8):1873–84.
Hayreh SS. Ischemic Optic Neuropathies. Springer; 2011.
Arnold AC, Wang MY. Ischemic Optic Neuropathies. In: Yanoff M, Duker JS, editors. Ophthalmology. 4th ed. Philadelphia: Elsevier Saunders; 2014. p. 884.
Lin MC, Hsu FM, Sheu SJ. Nonarteritic ischemic optic neuropathy. J Chinese Med Assoc [Internet]. 2007;70(2):61–4. Available from: http://dx.doi.org/10.1016/S1726-4901(09)70303-X
Hayreh SS. Symposium Management of ischemic optic neuropathies.
Arnold AC. Pathogenesis of nonarteritic anterior ischemic optic neuropathy. J Neuro-Ophthalmology. 2003;23(2):157–63.
Hayreh SS, Joos KM, Podhajsky PA, Long CR. Systemic Diseases Associated With Nonarteritic Anterior Ischémie Optic Neuropathy. Am J Ophthalmol [Internet]. 1994;118(6):766–80. Available from: http://dx.doi.org/10.1016/S0002-9394(14)72557-7
Cestari DM, Gaier ED, Bouzika P, Blachley TS, De Lott LB, Rizzo JF, et al. Demographic, Systemic, and Ocular Factors Associated with Nonarteritic Anterior Ischemic Optic Neuropathy. Ophthalmology [Internet]. 2016;123(12):2446–55. Available from: http://dx.doi.org/10.1016/j.ophtha.2016.08.017
Traustason OI, Feldon SE, Leemaster JE, Weiner JM. Anterior ischemic optic neuropathy: Classification of field defects by OctopusTM automated static perimetry. Graefe’s Arch Clin Exp Ophthalmol. 1988;226(3):206–12.
Zulkarnaen M, Rachman A, Nusanti S SM. Karakteristik Klinis dan Faktor Risiko Pasien Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) di Divisi Neuro-oftalmologi Departemen Mata RSUP dr. Cipto Mangunkusumo Periode Januari 2012 - Desember 2017. 2018;
Repka MX, Savino PJ, Schatz NJ, Sergott RC. Clinical profile and long-term implications of anterior ischemic optic neuropathy. Am J Ophthalmol. 1983;96(4):478–83.
Newman NJ, Scherer R, Langenberg P, Kelman S, Feldon S, Kaufman D, et al. The fellow eye in NAION: Report from the Ischemic Optic Neuropathy Decompression Trial Follow-up Study. Am J Ophthalmol. 2002;134(3):317–28.
Hayreh SS. Anterior ischaemic optic neuropathy. 1957;(I 974).
Atkins EJ, Bruce BB, Newman NJ, Biousse V. Treatment of Nonarteritic Anterior Ischemic Optic Neuropathy. Surv Ophthalmol. 2010;55(1):47–63.
Bordas M, Tabacaru B, Stanca TH. Non-arteritic anterior ischemic optic neuropathy – Case report. Rom J Ophthalmol. 2018;62(3):231–45.
Acheson JF, Sanders MD. COAGULATION ABNORMALITIES IN ISCHAEMIC OPTIC NEUROPATHY. 1994;89–92.
Levine SR, Crofts JW, Lesser GR, Floberg J, Welch KMA. Visual Symptoms Associated with the Presence of a Lupus Anticoagulant. Ophthalmology [Internet]. 95(5):686–92. Available from: http://dx.doi.org/10.1016/S0161-6420(88)33139-8
Nagy V, Kolozsvari B, Balogh Z, Csutak A, Kasza M, Nagy B, et al. Increased level of platelet P-selectin in nonarteritic anterior ischemic optic neuropathy. Graefe’s Arch Clin Exp Ophthalmol. 2013;251(3):917–22.
Talks SJ, Chong NHV, Gibson JM, Dodson PM. Fibrinogen, cholesterol and smoking as risk factors for non-arteritic anterior ischaemic optic neuropathy. Eye. 1995;9(1):85–8.
Nagia L, Huisingh C, Johnstone J, Kline LB, Clark M, Girard MJA, et al. Tissue Factor, Blood Coagulation, and Beyond: An Overview. J Vasc Surg. Fifth Edit. 2014;16(1):118.
Biousse V. Coagulation abnormalities and their neuro-ophthalmologic manifestations. Curr Opin Ophthalmol. 1999;10(6):382–93.
Spitze A, Hooten CG, Al-Zubidi N, Yalamanchili S, Lee AG. Arteritic anterior ischemic optic neuropathy (A-AION). Quest Answers Neuro-Ophthalmology A Case-Based Approach. 2014;77–87.
Slater BJ, Mehrabian Z, Guo Y, Hunter A, Bernstein SL. Rodent Anterior Ischemic Optic Neuropathy (rAION) induces regional retinal ganglion cell apoptosis with a unique temporal pattern. Investig Ophthalmol Vis Sci. 2008;49(8):3671–6.
Huang TL, Lin KH, Tsai RK. Treatment strategy for non-arteritic anterior ischemic optic neuropathy. Tzu Chi Med J [Internet]. 2013;25(3):135–8. Available from: http://dx.doi.org/10.1016/j.tcmj.2013.02.005
Chen J, Zhu J, Chen L, Hu C, Du Y. Steroids in the treatment of nonarteritic anterior ischemic optic neuropathy. Medicine (Baltimore). 2019;98–46.
Hayreh SS, Zimmerman MB. Non-arteritic anterior ischemic optic neuropathy: Role of systemic corticosteroid therapy. Graefe’s Arch Clin Exp Ophthalmol. 2008;246(7):1029–46.
Saxena R, Singh D, Sharma M, James M, Sharma P, Menon V. Steroids versus No Steroids in Nonarteritic Anterior Ischemic Optic Neuropathy A Randomized Controlled Trial. Ophthalmology [Internet]. 2018;1(3):1–5. Available from: https://doi.org/10.1016/j.ophtha.2018.03.032
Beck RW, Sohan Singh Hayreh, Podhajsky PA, Tan ES, Moke PS. Aspirin therapy in nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1997;123(2):212–7.
Duman R, Yavas GF, Veliyev I, Dogan M, Duman R. Structural changes of macula and optic disk of the fellow eye in patients with nonarteritic anterior ischemic optic neuropathy. Int Ophthalmol. 2019 Jun;39(6):1293–8.
Chang MY, Keltner JL, Moss HE, Pineles SL. Risk Factors for Fellow Eye Involvement in Nonarteritic Anterior Ischemic Optic Neuropathy. J Neuro-Ophthalmology. 2019;39(2):147–52.
Authors
Copyright (c) 2022 syntia nusanti, Dearaini Dearaini, Rasyidia Lakmita Putri, Rianti Wulandari Pratiwi
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.